[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:high-grade-b-cell-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":310,"states":332},"High Grade B-Cell Lymphoma",63,50,[8,16,22,29,35,41,47,54,60,66,72,78,84,90,96,102,108,114,120,126,132,138,144,149,155,161,167,173,179,186,191,197,203,209,215,221,227,233,239,245,251,257,263,269,275,280,286,292,298,304],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06249191","Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:09.641312Z","2026-07-19T19:36:05.128454Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06768905","IOMAB-CAR-T Followed by CAR-T Cell Therapy in R\u002FR DLBCL",[12],"2026-08-26T02:19:16.454910Z","2026-05-05T02:43:29.506243Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT04002947","Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma",[26],"Phase 2","2026-08-26T02:17:04.346841Z","2026-05-05T02:43:28.535260Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06687772","CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant",[26],"2026-08-26T02:15:40.343619Z","2026-05-05T02:43:27.846837Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT07316010","Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma",[26],"2026-08-26T02:19:27.519777Z","2026-05-05T02:35:31.631978Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06806033","A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed\u002FRefractory Aggressive B-Cell Non-Hodgkin's Lymphoma",[26],"2026-08-26T02:15:56.561131Z","2026-05-05T02:35:31.607270Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT07226843","A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers",[51],"Phase 1","2026-08-26T02:15:58.452248Z","2026-07-05T05:32:16.666342Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06649812","Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and\u002For Refractory Aggressive B-cell Lymphoma",[26],"2026-08-26T02:16:17.877565Z","2026-06-16T05:54:07.922088Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05600686","Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma",[26],"2026-08-26T02:16:21.385056Z","2026-05-05T02:43:29.693214Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06828991","A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP",[26],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.283059Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05890352","Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment",[26],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:28.725480Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT05256641","Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma",[12],"2026-08-26T02:19:19.975067Z","2026-05-05T02:43:28.530741Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06765317","A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma",[26],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:28.346447Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06500273","Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL",[26],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:28.207810Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06458439","Epcoritamab-CAR T Cells for Large B-cell Lymphomas",[26],"2026-08-26T02:17:54.420226Z","2026-05-05T02:43:28.016787Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT06905509","Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",[26],"2026-08-26T02:15:13.282904Z","2026-05-05T02:43:27.809747Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT05755087","Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma",[51],"2026-08-26T02:17:39.857430Z","2026-05-05T02:43:27.642521Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT07365306","Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[26],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:27.484467Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT07069699","Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene",[12],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:27.175695Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT06015880","Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[51],"2026-08-26T02:16:27.227548Z","2026-05-05T02:43:26.961325Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT07042438","Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells",[26],"2026-08-26T02:15:11.740957Z","2026-05-05T02:35:31.730111Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT06784726","Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T",[26],"2026-08-26T02:18:38.077159Z","2026-05-05T02:35:31.722685Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":88,"content_modified":148},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[51],"2026-07-19T19:36:05.125264Z",{"nct_id":150,"title":151,"phases":152,"status":13,"updated_at":153,"content_modified":154},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[26],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":156,"title":157,"phases":158,"status":13,"updated_at":159,"content_modified":160},"NCT07123454","A Phase I\u002FII Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma",[12],"2026-08-26T02:19:29.119921Z","2026-07-05T05:32:16.737268Z",{"nct_id":162,"title":163,"phases":164,"status":13,"updated_at":165,"content_modified":166},"NCT06788964","Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)",[26],"2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.700465Z",{"nct_id":168,"title":169,"phases":170,"status":13,"updated_at":171,"content_modified":172},"NCT05260957","CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory\u002FRelapsed Aggressive Non-Hodgkin's Lymphoma (NHL).",[26],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:29.501361Z",{"nct_id":174,"title":175,"phases":176,"status":13,"updated_at":177,"content_modified":178},"NCT07098364","ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed\u002FRefractory Large B-Cell Lymphoma",[12],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:29.072273Z",{"nct_id":180,"title":181,"phases":182,"status":13,"updated_at":184,"content_modified":185},"NCT07188558","A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",[183],"Phase 3","2026-08-26T02:18:37.277498Z","2026-05-05T02:43:29.052132Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":153,"content_modified":190},"NCT05077527","Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma",[51],"2026-05-05T02:43:29.044473Z",{"nct_id":192,"title":193,"phases":194,"status":13,"updated_at":195,"content_modified":196},"NCT06209619","CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma",[51],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:28.853554Z",{"nct_id":198,"title":199,"phases":200,"status":13,"updated_at":201,"content_modified":202},"NCT06285825","A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia",[26],"2026-08-26T02:16:03.788292Z","2026-05-05T02:43:28.728703Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":207,"content_modified":208},"NCT03136146","Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma\u002FLeukemia, or Double-Hit Lymphoma\u002FLeukemia",[26],"2026-08-26T02:18:35.425468Z","2026-05-05T02:43:28.565200Z",{"nct_id":210,"title":211,"phases":212,"status":13,"updated_at":213,"content_modified":214},"NCT02393157","Obinutuzumab and ICE Chemotherapy in Refractory\u002FRecurrent CD20+ Mature NHL",[26],"2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.289405Z",{"nct_id":216,"title":217,"phases":218,"status":13,"updated_at":219,"content_modified":220},"NCT04231877","Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",[51],"2026-08-03T01:58:01.892442Z","2026-05-05T02:43:28.077600Z",{"nct_id":222,"title":223,"phases":224,"status":13,"updated_at":225,"content_modified":226},"NCT05418088","Genetically Engineered Cells (Anti-CD19\u002FCD20\u002FCD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",[51],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.982458Z",{"nct_id":228,"title":229,"phases":230,"status":13,"updated_at":231,"content_modified":232},"NCT01371630","Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:27.961680Z",{"nct_id":234,"title":235,"phases":236,"status":13,"updated_at":237,"content_modified":238},"NCT06026319","CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",[51],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:27.943297Z",{"nct_id":240,"title":241,"phases":242,"status":13,"updated_at":243,"content_modified":244},"NCT07082803","TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas",[51],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:27.605782Z",{"nct_id":246,"title":247,"phases":248,"status":13,"updated_at":249,"content_modified":250},"NCT06533579","Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",[12],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.324190Z",{"nct_id":252,"title":253,"phases":254,"status":13,"updated_at":255,"content_modified":256},"NCT07097363","Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma",[26],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:27.261789Z",{"nct_id":258,"title":259,"phases":260,"status":13,"updated_at":261,"content_modified":262},"NCT05672251","Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[26],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:27.249867Z",{"nct_id":264,"title":265,"phases":266,"status":13,"updated_at":267,"content_modified":268},"NCT07195916","A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies",[51],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:27.041939Z",{"nct_id":270,"title":271,"phases":272,"status":13,"updated_at":273,"content_modified":274},"NCT06811272","Outpatient Epcoritamab as 2L in NTE R\u002FR DLBCL",[26],"2026-08-26T02:19:08.862440Z","2026-05-05T02:43:26.689921Z",{"nct_id":276,"title":277,"phases":278,"status":13,"updated_at":118,"content_modified":279},"NCT06834373","Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy",[26],"2026-05-05T02:43:26.687370Z",{"nct_id":281,"title":282,"phases":283,"status":13,"updated_at":284,"content_modified":285},"NCT06536049","Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma",[12],"2026-08-26T02:16:47.762107Z","2026-05-05T02:43:26.676281Z",{"nct_id":287,"title":288,"phases":289,"status":13,"updated_at":290,"content_modified":291},"NCT06173518","A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",[51],"2026-08-26T02:17:21.315591Z","2026-05-05T02:35:31.644184Z",{"nct_id":293,"title":294,"phases":295,"status":13,"updated_at":296,"content_modified":297},"NCT06736613","A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma",[26],"2026-08-26T02:19:01.741747Z","2026-05-05T02:43:29.366355Z",{"nct_id":299,"title":300,"phases":301,"status":13,"updated_at":302,"content_modified":303},"NCT07654426","The CARDIOPROTECT Trial",[26],"2026-08-26T02:16:52.995882Z","2026-06-17T19:21:16.687697Z",{"nct_id":305,"title":306,"phases":307,"status":13,"updated_at":308,"content_modified":309},"NCT04300998","Study of CAR-T Therapy in Older Patients",[],"2026-08-26T02:15:18.897219Z","2026-05-13T02:55:06.245539Z",[311,315,318,321,324,328],{"biomarker":312,"count":313,"slug":314},"BCL2 Gene",11,"bcl2-gene",{"biomarker":316,"count":313,"slug":317},"BCL6 Gene","bcl6-gene",{"biomarker":319,"count":313,"slug":320},"MS4A1 Gene","ms4a1-gene",{"biomarker":322,"count":313,"slug":323},"MYC Gene","myc-gene",{"biomarker":325,"count":326,"slug":327},"CD19 Gene",9,"cd19-gene",{"biomarker":329,"count":330,"slug":331},"MBD5 wt Allele",3,"mbd5-wt-allele",[333,337,341,345,348,352,355,359,362,365,368,371,375,378,382,385,388,391,395,398,401,404,407,411],{"state":334,"count":335,"slug":336},"California",23,"california",{"state":338,"count":339,"slug":340},"New York",19,"new-york",{"state":342,"count":343,"slug":344},"Ohio",17,"ohio",{"state":346,"count":343,"slug":347},"Texas","texas",{"state":349,"count":350,"slug":351},"Florida",13,"florida",{"state":353,"count":313,"slug":354},"Pennsylvania","pennsylvania",{"state":356,"count":357,"slug":358},"Minnesota",10,"minnesota",{"state":360,"count":357,"slug":361},"Tennessee","tennessee",{"state":363,"count":357,"slug":364},"Washington","washington",{"state":366,"count":326,"slug":367},"Illinois","illinois",{"state":369,"count":326,"slug":370},"Oregon","oregon",{"state":372,"count":373,"slug":374},"Massachusetts",8,"massachusetts",{"state":376,"count":373,"slug":377},"North Carolina","north-carolina",{"state":379,"count":380,"slug":381},"Arizona",7,"arizona",{"state":383,"count":380,"slug":384},"Colorado","colorado",{"state":386,"count":380,"slug":387},"Missouri","missouri",{"state":389,"count":380,"slug":390},"Virginia","virginia",{"state":392,"count":393,"slug":394},"Georgia",6,"georgia",{"state":396,"count":393,"slug":397},"Michigan","michigan",{"state":399,"count":393,"slug":400},"Oklahoma","oklahoma",{"state":402,"count":393,"slug":403},"Utah","utah",{"state":405,"count":393,"slug":406},"Wisconsin","wisconsin",{"state":408,"count":409,"slug":410},"Maryland",5,"maryland",{"state":412,"count":409,"slug":413},"Nebraska","nebraska"]